

ASX RELEASE

2 May 2022

Respiri announces completion of share placement

Highlights

- \$1.6 million (before costs) to be raised through a share placement of at \$0.045 (4.5 cents) per fully paid ordinary share.
- The Placement will occur via one tranche and expects to be settled by Thursday 5th May 2022.
- Approximately 36 million new fully paid ordinary shares to be issued across the Placement (the **Offer**)
- The Offer proceeds will be used to accelerate Respiri's commercialisation and roll-out strategy in the USA

Respiri Limited (ASX:RSH) (**Respiri** or the **Company**), an eHealth SaaS company supporting respiratory health management, is pleased to announce that it has received commitments to raise \$1.6 million (before costs) in new equity via a placement of new fully paid ordinary shares to institutional, professional and sophisticated investors (**Placement**).

The Placement will result in the issue of approximately 36 million fully paid ordinary shares in the Company (**New Shares**) at an issue price of \$0.045 (4.5 cents) per New Share, which is a 11.8% discount to the last close price on 26 April 2022, and a 26.0% discount to the 5-day VWAP ending on 26 April 2022. The shares will be pursuant to its 15% placement capacity under ASX Listing Rule 7.1.

The New Shares will rank equally with existing fully paid ordinary shares in the Company (Shares).

The funds raised under the Offer will be used to accelerate Respiri's commercialisation and roll-out strategy in the USA.

The Company anticipates settlement of the Placement Shares to occur on Thursday 5th May 2022 and intends to issue the Placement Shares without a disclosure document on Friday 6th May 2022.

Mr Alastair Beard
Company Secretary
Respiri Limited

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 2 May 2022 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

™ wheezo is a trademark of Respiri Limited